CAMK2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL414672	0.41	5/20
SCHEMBL234334	1.00	4/20
SCHEMBL276090	0.66	3/20
Rosoxacin (SCHEMBL135645)	0.48	3/20
SCHEMBL145695	0.45	3/20
SCHEMBL416549	0.40	3/20
Alvocidib (SCHEMBL3651)	1.00	2/20
Alvocidib (SCHEMBL3652)	1.00	2/20
Sunitinib (SCHEMBL8081)	1.00	2/20
Sunitinib (SCHEMBL8082)	1.00	2/20
Bi-2536 (SCHEMBL372489)	1.00	2/20
SCHEMBL419365	1.00	2/20
Sunitinib (SCHEMBL18648)	0.92	2/20
SCHEMBL376236	0.88	2/20
SCHEMBL376821	0.85	2/20
Sunitinib (SCHEMBL55459)	0.84	2/20
SCHEMBL375825	0.83	2/20
SCHEMBL376040	0.83	2/20
SCHEMBL375839	0.81	2/20
SCHEMBL424307	0.81	2/20

Clinical trials — most relevant to CAMK2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia	PHASE4	COMPLETED
Ketamine Treatment Effects on Synaptic Plasticity in Depression	PHASE4	COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?	PHASE2	COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)	EARLY_PHASE1	RECRUITING
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CAMK2B binder may also engage these)

Protein	Name	Similarity
P11730	—	1.000	P11730 →
P08413	—	0.997	P08413 →
Q6DGS3	—	0.996	Q6DGS3 →
Q3MHJ9	—	0.996	Q3MHJ9 →
P28652	—	0.995	P28652 →
Q66I46	—	0.995	Q66I46 →
Q6DEH3	—	0.995	Q6DEH3 →
Q923T9	—	0.994	Q923T9 →
Q6PHZ2	—	0.994	Q6PHZ2 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.994	landscape →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	0.994	landscape →
Q9ZUZ2	—	0.993	Q9ZUZ2 →
A8WXF6	—	0.993	A8WXF6 →
Q66JF3	—	0.992	Q66JF3 →
PAK3	Serine/threonine-protein kinase PAK 3	0.992	landscape →
O77708	—	0.992	O77708 →
O80673	—	0.992	O80673 →
O08875	—	0.992	O08875 →
Q7TNL3	—	0.992	Q7TNL3 →
Q4G050	—	0.992	Q4G050 →
Q8BRK8	—	0.992	Q8BRK8 →
Q17QV9	—	0.992	Q17QV9 →
P15791	—	0.992	P15791 →
Q91VB2	—	0.991	Q91VB2 →
P08414	—	0.991	P08414 →
Q6YY75	—	0.991	Q6YY75 →
Q9FG74	—	0.991	Q9FG74 →
Q8CIP4	—	0.991	Q8CIP4 →
Q9FX86	—	0.990	Q9FX86 →
Q2HJF7	—	0.990	Q2HJF7 →